KemPharm, Inc. Stock News

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Officer Neil F.

Q2 2025 net revenue of $25.9 million , driven by product net revenue of $21.8 million

Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pic...

CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA® (sodium phenylbutyrate) are being presented at the 42nd Annual Meeting of the Southeastern Re...

CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term Efficacy and Safety of Arimoclomol in Niemann-Pick Disease Type C: Final Results of the Phase 2/3 NPC-002 48-month Open-label Extension Trial”...

Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D.